A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Clinical Study to Evaluate the Efficacy and Safety of SHR0302 in Moderate to Severe Active Rheumatoid Arthritis Subjects With Inadequate Response to csDMARDs.

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 17 Jul 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ivarmacitinib (Primary)
Indications Rheumatoid arthritis
Focus Registrational; Therapeutic Use
Sponsors Jiangsu Hengrui Medicine Co.

Most Recent Events

15 Jun 2024 Results assessing efficacy and safety of SHR0302 in pts with moderate to severe active RA who had an inadequate response to csDMARDs presented at the 25th Annual Congress of the European League Against Rheumatism
13 Nov 2023 Status changed from recruiting to completed.
16 Sep 2020 Planned End Date changed from 1 Aug 2022 to 1 Dec 2022.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight